Cure Childhood Cancer

CURE Blog


August 6th, 2012

CURE Finds Guidance Through Scientific Advisory Council

If the key to finding the cure for childhood cancer is research, how do we decide which research projects to fund? In order to guide our choices we look to our Scientific Advisory Council.

Comprised of doctors, scientists and experts, the council studies the status of current research funded by CURE Childhood Cancer, as well as that funded since 2006. They assess the outcomes and identify successful projects to make funding recommendations that align with CURE’s research goals.

Currently, our focus is on projects aimed at the 20% of children diagnosed with cancer who are not surviving today’s methods of treatment. With that in mind, in fiscal year 2012-2013, we will fund research involving the highest risk pediatric cancers that fall into one of the following categories:

1. Innovative clinical therapy and transplantation

2. Mechanism of drug resistance and drug discovery

3. Study of novel tumor biomarkers for diagnostic, prognostic, therapeutic and
vaccine development potential

4. Genetics and/or Genomics as related to cancer development, resistance,
mechanism

“CURE continues to be a very significant supporter of childhood cancer research, and I’m pleased to assist in selecting promising research projects for CURE funding,” says Harry Findley, PhD, Emeritus Professor at Emory University. ”Our goal is not only to identify cutting-edge research projects, but also to provide helpful feedback to the researchers whenever possible.”

The CURE Scientific Advisory Council includes:

  • Kevin L. Karem, PhD: CDC Scientist – Council Chair
  • Terri Ades, DNP, FNP-BC, AOCN: Director, Cancer Information, American Cancer Society
  • Carlos Alvarado, MD: Emeritus Professor, Emory University
  • Harry Findley, PhD: Emeritus Professor, Emory University
  • John D. Bergsagel, MD, Oncologist at Children’s Healthcare of Atlanta at Scottish Rite and Assistant Professor of Pediatrics, Department of Pediatrics, Emory University School of Medicine
  • William H. Chambers, PhD, Director, Clinical Cancer Research and Immunology, American Cancer Society
  • Leon Bernal-Mizrachi, Assistant Professor of Hematology and Medical Oncology, Winship Cancer Institute of Emory University
  • Richard J. Woodcock, MD, Neuroradiologist, MRI & Imaging of Georgia

For information on the 2012-2013 research initiatives that CURE is supporting, click here.


July 24th, 2012

CURE Talks with Dr. Woods (Part 5)

CURE Childhood Cancer sat down with Dr. Woods, the Director at the Aflac Cancer & Blood Disorders Center at Children’s Healthcare of Atlanta. In this fifth video, we asked Dr. Woods if he believes we can find a cure for childhood cancer in our lifetime.


June 29th, 2012

CURE Talks with Annamarie Robb

As we reach the conclusion of the week dedicated to honoring the 5 year anniversary of the passing of Sam Robb, we wanted to share with you an interview held with Annamarie Robb, Sam’s mother. In this video Annamarie discusses how CURE Childhood Cancer supported the Robb family, how the Robb family continues to support CURE, and why it is important for CURE to continue to fund childhood cancer research.

For more information on The Sam Robb Fund please click here.


June 21st, 2012

CURE Talks to Dr. Woods (Part 3)

CURE sat down with Dr. Woods, the Director at the Aflac Cancer Center at Children’s Healthcare of Atlanta. In this third video, we asked Dr. Woods why it is important for local organizations to support childhood cancer research.

Stayed tuned in the following weeks for additional videos.


June 15th, 2012

CURE Talks to Dr. Woods (Part 2)

Late last year, CURE Childhood Cancer sat down with Dr. William Woods, Director of the Aflac Cancer Center at Children’s Healthcare of Atlanta. We are pleased to present the second installment in a series of videos of our conversation with Dr. Woods, in which he discusses how CURE funding has helped him over the years.

 

 

Stayed tuned in the following weeks for additional videos.


June 7th, 2012

Research Initiatives Show Progress in Finding a CURE

CURE Childhood Cancer is dedicated to conquering childhood cancer through funding targeted research. Currently, we’re supporting eleven specific projects, most of which focus on finding effective treatments for the 20% of kids who do not survive.

As we wrap up the 2011-2012 year we wanted to spend some time in a series of blogs giving you a summary of the research initiatives that we helped fund throughout the year. In the past 12 months we have committed more than $1.2 million in research grants and believe it is important for all of us to understand the progress of these research initiatives.

Below is a summary of Dr. Kelly Goldsmith’s research study and the progress that it has made in the past year.

Goldsmith versus Neuroblastoma

Dr. Goldsmith is conducting a study that addresses an important area of research in the mechanisms of tumor growth and treatment resistance in high-risk neuroblastoma, which may result in improved treatment strategies. It explores several areas, including the pathway that prevents normal regulated cell death (apoptosis), that allows tumor to continue its growth; and it seeks to characterize the regulation of an important genetic pathway causing chemotherapy resistance.

Recently, the study was able to identify a protein (mcl-1) that is acting as a barrier to treatment, by promoting chemotherapy resistance. his work has shown that this protein is regulated or manged by another called EGFR, and suggests that treatments should target the regulating protein, EGFR. This has potential to improve success in treating resistance in relapsed tumors. It has also identified an important molecule, Bax, that is de-activated in these tumors, which leads to failure of apoptosis. Future work will try to characterize what causes that de-activation, and will look to ways to reverse that.

The results of this research will be published in Cancer Research and the data is expected to be used for the Department of Defense Pediatric Grant application this year.

 

 


May 31st, 2012

CURE Talks to Dr. Woods (Part 1)

Late last year, CURE Childhood Cancer sat down with Dr. William Woods, Chair of Hematology/Oncology at the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta. We are pleased to present the first installment in a series of videos of our conversation with Dr. Woods, in which he discusses how CURE funding has helped him over the years.

Stay tuned in the upcoming weeks for the rest of the videos.


May 11th, 2012

New Act Gives Hope for Childhood Cancer Research

Pediatric cancer remains the number one disease killer of American children, with about 35 children diagnosed every day. However, since 1980, the Food and Drug Association (FDA) has approved only one new drug for treatment of childhood cancer, compared to 50 for adults.

This is often a result of pharmaceutical companies hesitancy to develop drugs for rare pediatric diseases because it requires making an investment in products that are unlikely to cover the high costs associated with their research, development, marketing and distribution. Developing products for children is particularly challenging because of the difficulties associated with conducting clinical trials on this patient population. 

However, Congressmen Michael McCaul of Texas and G.K. Butterfield of North Carolina have recently authored a provision to combat this particular issue.

Yesterday, the House Energy and Commerce Committee approved The Creating Hope Act of 2011, which will incentivize pharmaceutical companies to develop new drugs for children with rare pediatric diseases, such as childhood cancers.

“Children living with these life threatening conditions need access to newly developed drugs,” said Congressman Butterfield.  ”Whether a disease is rare or common, the need for effective care and potential cures is the same. The Creating Hope Act provides a much-needed incentive to promote research and development that will ultimately save lives.”

According to Congressman McCaul, The Creating Hope Act will offer the best chance of encouraging pharmaceutical companies to develop treatments for children at no cost to taxpayers.

“This legislation will give hope to countless numbers of children and their families who are unable to treat their disease because of a lack of adequate treatments,” said Congressman McCaul.

For more information on The Creating Hope Act you can click here.


April 13th, 2012

CURE Needs your Help in Altering the Effectiveness of Two Childhood Cancer Laws

Ruth Hoffman, the Executive Director of The American Childhood Cancer Association, recently spoke out about a very important topic relating to our children and their cancer treatment. We support Ruth’s words wholeheartedly and urge the CURE Childhood Cancer community to take action:

“Dear Childhood Cancer Advocate:

The Best Pharmaceuticals for Children Act (BPCA) and Pediatric Research Equity Act (PREA) are two critical federal laws that provide incentives and requirements for pharmaceutical companies to test their drugs for use in children. BPCA and PREA expire on October 1, 2012, and Congress is currently working to reauthorize these laws in advance of their sunset date.

While BPCA and PREA have made significant research advances in how medicines can be used in children in general, the laws have had a very modest impact on the development of new drugs for children with cancer. In fact, PREA itself has had no meaningful impact. We need your help to modify this law so that it can help children with cancer.

Under current PREA law, companies are required to study their drugs in children only if the drug is developed for a disease that occurs in both adults and children. Because common adult cancers – such as breast, colon, lung and prostate typically do not affect children, companies receive waivers so they are not required to study these drugs in children with cancer even though they may hold great promise.

The American Childhood Cancer Organization is partnering with The Children’s Cause for Cancer Advocacy, The Alliance for Childhood Cancer, and the Children’s Oncology Group (COG) to advocate for a proposal  to strengthen PREA so that it can be used to encourage companies to evaluate whether their new cancer drugs can provide better and more effective treatment options for children with cancer “if the target of the drug for an adult oncologic indication is included in the drug’s label and is highly relevant to any pediatric cancer to which it could apply.”

Please take action today by contacting your Representatives and Senators to urge them to strengthen PREA for children with cancer. To see the language proposed for PREA that will advance therapies for children with cancer, and to send a letter to your Members of Congress, click this link.

Thank you for adding your voice to this critical effort to help improve treatments for our children.”


March 22nd, 2012

We Need your Signature: NIH Petition

CURE Childhood Cancer understands that funding research saves lives. A very important petition was recently submitted to the White House proposing an increase in funding for the National Institutes of Health (NIH). We support this petition wholeheartedly and ask each of you read this post and sign the petition today. Please help spread the word so the required 25,000 signatures will be obtained.

Funding for the NIH supports a massive, vital engine that improves our nation’s health,advances research, promotes medical education, and generates 1,000,000 jobs, in all 50 states. It has been funded at decreasing (flat or sub-inflationary) rate since 2003. Thousands of promising careers, research projects, and laboratories have been aborted or closed down because of this funding crisis. The proposed flat $30.7 billion budget will bring this crisis to a boiling point. Instead, this petition proposes a $33 billion NIH budget for fiscal year 2013.

In order for a petition to stay active, it must receive 25,000 signatures over a 30-day period. A similar petition was started by Stephen Meltzer from Johns Hopkins and expired on 3/18/12 with 24,554 signatures. The petition was only 446 short. This cannot happen again!

As of right now, the new petition still needs approximately 17,000 signatures. We know how strong the support is in the CURE Community, so we are confident we can help this petition reach 25,000 signatures. We are simply asking each of you to view the petition, create an account, and add your signature.

We can do this!


  •  

    Screen Shot 2013-05-06 at 4.25.29 PM

    Nacho Average Taco

    For May and June, order the CURE taco at Red Pepper Taqueria and $1 will be donated to CURE. The taco features chargrilled calamari, crispy eggplant, tomato, onion, sorrel, and ginger pico.


  • Screen Shot 2013-05-14 at 2.49.59 PM

    Home by Dark - Singer/Songwriter Show

    Saturday June 1st at 8PM at Chukkar Farm in Alpharetta, GA. A portion of the proceeds will benefit CURE. Bring your own chairs and picnic for this beautiful outdoor music event. Click here to learn more.